Core Insights - Persistent Systems has launched an AI-powered Generative Molecules and Virtual Screening solution in collaboration with NVIDIA to enhance drug discovery in the Healthcare and Life Sciences (HLS) sector [1][6]. Group 1: Collaboration and Technology - The partnership aims to accelerate the development of AI solutions for HLS organizations, enabling them to transition from AI experimentation to real-world applications in regulated environments [2][6]. - Persistent will utilize NVIDIA's AI Enterprise for specialized Life Sciences R&D, focusing on preclinical research through high-fidelity molecular simulation and virtual screening [3][5]. Group 2: Product Development - Persistent has developed the Generative Molecules and Virtual Screening (GenMoIVS) solution, which employs NVIDIA's BioNeMo platform and NeMo Agent Toolkit to facilitate AI-driven molecular simulations [4][5]. - The GenMoIVS solution aims to streamline drug discovery workflows by enabling continuous decision-making across virtual screening and experimental planning, thereby improving success rates in clinical development [4][6]. Group 3: Infrastructure and Capabilities - The collaboration will leverage NVIDIA's accelerated computing resources and open models to enhance the GenMoIVS solution, allowing for cost-effective application development and scaling [5][6]. - Persistent plans to expand its AI and LLM engineering capabilities by utilizing NVIDIA's infrastructure and training resources, aiming to deliver sophisticated data and AI platforms for clients [6]. Group 4: Company Overview - Persistent Systems is a global leader in Digital Engineering and Enterprise Modernization, with over 26,500 employees across 18 countries, and is committed to innovation and client success [7]. - The company has achieved significant growth, with a 468% increase in brand value since 2020, making it the fastest-growing IT services brand in the 'Brand Finance India 100' 2025 Report [7].